Fed Circuit Watch: No Standing to Appeal When Biosimilar Product Withdrawn
Sometimes substantive patent issues are never dealt with in cases, but rather dispositive issues are handled by procedural mechanisms. One case in point is Momenta Pharms., Inc. v. Bristol-Myers...
PTAB Releases Revision to Operating Procedures for Cases Remanded from Federal Circuit
On November 16, 2017, the Patent Trial and Appeal Board (PTAB) revised its Standard Operating Procedures 9 (SOP9) involving cases remanded for further review from the Federal Circuit. These standard...
